EUVIMEDEUVIMED entdecken
Open Access

Host-directed nanotherapy for the treatment and imaging of tuberculous meningitis

Elizabeth W Tucker, John Kim, Clara Erice, Anjali Sharma, Nerketa N L Damiba, Alvaro A Ordonez, Javier Allende Labastida, Nirnath Sah, Filipa Mota, Patricia de Jesus, Rhea Saini, Kelly F Schiaffino und 3 weitere

Theranostics · 2026

DOI: 10.7150/thno.125729 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2026. Verfasst von Elizabeth W Tucker und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Hauptthemen laut MEDLINE: Tuberculosis, Meningeal, Theranostic Nanomedicine. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Tuberculous meningitis (TB meningitis) is a devastating infection where the host immune response drives brain injury. Standard adjunctive corticosteroids often fail to prevent neurological sequelae or improve survival in many populations. Host-directed therapies that can cross the blood-brain barrier (BBB) and reduce neuroinflammation are urgently needed. We evaluated a hydroxyl-terminated polyamidoamine (PAMAM) dendrimer as a theranostic nanoplatform to visualize and treat microglia-mediated neuroinflammation in a young rabbit model of TB meningitis.

Methods

A novel radiolabeled dendrimer (124I-dendrimer) was synthesized for noninvasive positron emission tomography (PET) imaging, with post-mortem gamma counting and fluorescent-labeled dendrimer (D-Cy5) confirming biodistribution. For therapy, rabbits with TB meningitis (i.e., infected) received weekly intravenous dendrimer-N-acetyl cysteine (D-NAC) or phosphate buffered saline (PBS). After two weeks, treatment efficacy was evaluated with longitudinal neurobehavioral scores and multimodal PET (18F-FDG for glucose metabolism, 18F-py-albumin for BBB integrity, and 124I-DPA-713 for microglial/macrophage activation). Post-mortem analyses included bacterial burden (colony-forming units [CFU]), cerebrospinal fluid (CSF) protein and cytokine levels, and brain immunohistochemistry for glial and white matter markers.

Results

124I-Dendrimer demonstrated selective accumulation within brain lesions, co-localizing primarily with activated microglia. D-NAC significantly improved neurological outcomes and attenuated neuroinflammation and brain injury, even without antimicrobial therapy. Longitudinal PET imaging confirmed D-NAC efficacy, showing decreased neuroinflammation (124I-DPA-713) and improved BBB integrity (18F-py-albumin). Post-mortem analyses corroborated these findings, demonstrating that D-NAC reduced microglial inflammation and IL-17a levels, while improving myelination and BBB integrity.

Conclusions

This study establishes D-NAC as a promising host-directed theranostic strategy for TB meningitis and supports the clinical potential of dendrimer nanoplatforms to diagnose and treat central nervous system infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, MeningealTheranostic NanomedicineAnimalsDendrimersRabbitsPositron-Emission TomographyBlood-Brain BarrierHost-Directed TherapyDisease Models, AnimalMicrogliaBrainIodine Radioisotopes

Stichwörter der Autor:innen

PET imagingdendrimerhost-directed therapymicrogliatuberculous meningitis

Substanzen

DendrimersPAMAM StarburstIodine Radioisotopes

Autor:innen und Institutionen

  • Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Center for Nanomedicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Tucker, E. W., Kim, J., Erice, C., Sharma, A., Damiba, N. N. L., Ordonez, A. A., Allende Labastida, J., Sah, N., Mota, F., de Jesus, P., Saini, R., Schiaffino, K. F., Jain, S. K., Kannan, R. M., & Kannan, S. (2026). Host-directed nanotherapy for the treatment and imaging of tuberculous meningitis. Theranostics. https://doi.org/10.7150/thno.125729

Vancouver

Tucker EW, Kim J, Erice C, Sharma A, Damiba NNL, Ordonez AA, et al. Host-directed nanotherapy for the treatment and imaging of tuberculous meningitis. Theranostics. 2026. doi:10.7150/thno.125729

BibTeX
@article{Tucker2026,
  author = {Tucker, Elizabeth W and Kim, John and Erice, Clara and Sharma, Anjali and Damiba, Nerketa N L and Ordonez, Alvaro A and Allende Labastida, Javier and Sah, Nirnath and Mota, Filipa and de Jesus, Patricia and Saini, Rhea and Schiaffino, Kelly F and Jain, Sanjay K and Kannan, Rangaramanujam M and Kannan, Sujatha},
  title = {Host-directed nanotherapy for the treatment and imaging of tuberculous meningitis},
  journal = {Theranostics},
  year = {2026},
  doi = {10.7150/thno.125729}
}
Kostenlos starten →